🔥 今日推荐 #生信前沿技术 #空间代谢组学 #肿瘤代谢

IRG1/衣康酸通过抑制G6PD重编程巨噬细胞和肺肿瘤代谢

IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition

📅 2026-06-03  |  📰 Cell Metabolism  |  ⭐ IF 29.0

⭐ Claude 五维度评估
逻辑完整性
9
★★★★
方法学水平
9
★★★★
创新性
8
★★★★
可借鉴性
9
★★★★
临床转化
8
★★★★
总分：43/50 ⭐
📝 文章速览

肿瘤相关巨噬细胞(TAMs)在肿瘤发生发展中兼具促癌和抑癌双重角色。本研究聚焦于免疫应答基因1(IRG1)及其代谢产物衣康酸(itaconate)在肺癌中的抑癌功能。

核心发现：空间代谢组学揭示肺肿瘤区域内源性衣康酸显著耗竭；scRNA-seq鉴定巨噬细胞为IRG1主要来源；IRG1敲除促进肺肿瘤生长。机制上，衣康酸通过抑制G6PD活性阻断戊糖磷酸途径(PPP)，重塑癌症细胞和促癌巨噬细胞的代谢格局。4-辛基衣康酸(Octyl Ita)在体内、体外及人肺切片模型中均显示抑癌效果。

关键词： itaconate G6PD lung cancer tumor-associated macrophages spatial metabolomics pentose phosphate pathway

👥 研究团队

Siavash Mansouri, Golnaz Hesami, Annika Karger, Ujjwal Neogi, et al.

📄 Cell Metabolism, 2026 | DOI: 10.1016/j.cmet.2026.05.005 | PMID: 42235511

📊 Figure 1 | 空间代谢组学揭示肺肿瘤微环境中衣康酸耗竭
Figure 1
Figure 1 | Fig. 1: Spatial metabolomics reveals itaconate depletion in lung tumor microenvironment. Mass spectrometry imaging shows that endogenous itaconate is markedly depleted within tumor regions compared to adjacent non-tumor tissue in human and mouse lung cancer samples. Quantitative analysis confirms significant reduction in itaconate levels across multiple lung cancer subtypes.
🔬 复现建议：用户的课题也可借鉴此空间代谢组学工作流：使用DESI-MSI或MALDI-MSI对肿瘤组织进行空间代谢物成像，定位乳酸(lactate)在肿瘤区域的分布异质性。结合H&E染色和免疫荧光，可将乳酸浓度梯度与mitoxyperiosis marker(如线粒体质膜距离)进行空间关联分析。
📊 Figure 2 | 单细胞测序锁定巨噬细胞为IRG1/衣康酸主要来源
Figure 2
Figure 2 | Fig. 2: Single-cell RNA-seq identifies macrophages as the primary source of IRG1/itaconate. scRNA-seq profiling of human and mouse lung tumors reveals that IRG1 is predominantly expressed in macrophage populations, not in tumor cells or other immune cell types. Validation by immunofluorescence and flow cytometry confirms macrophage-specific IRG1 expression.
🔬 复现建议：在用户的乳酸化课题中，同样可用scRNA-seq鉴定肿瘤微环境中产乳酸的主要细胞亚群（如T细胞、巨噬细胞或肿瘤细胞自身），并分析不同细胞亚群的乳酸转运蛋白(MCT1/4)表达差异，推断乳酸从来源细胞到靶细胞的旁分泌路径。
📊 Figure 3 | IRG1基因敲除显著促进肺肿瘤生长
Figure 3
Figure 3 | Fig. 3: IRG1 knockout promotes lung tumor growth in vivo. Irg1-/- mice and bone marrow transplantation models demonstrate that IRG1 depletion in macrophages leads to significantly increased lung tumor burden across multiple mouse models (KrasG12D, LLC, urethane). Tumor growth kinetics, nodule number, and survival are all worsened upon IRG1 loss.
🔬 复现建议：用户可利用CRISPR/Cas9敲除LDHA（关键产乳酸酶）或PCAF（乳酸转移酶），观察mitoxyperiosis水平变化。本研究的骨髓移植模型也值得参考：通过骨髓嵌合体实验区分髓系和非髓系来源的乳酸对肿瘤的影响。
📊 Figure 4 | 衣康酸直接靶向抑制G6PD，阻断戊糖磷酸通路
Figure 4
Figure 4 | Fig. 4: Itaconate inhibits G6PD to suppress pentose phosphate pathway (PPP). Mechanistic studies show that itaconate directly binds to and inhibits glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of PPP. G6PD inhibition by itaconate reduces NADPH production and nucleotide synthesis, suppressing cancer cell proliferation. Rescue experiments with G6PD overexpression reverse itaconate's anti-tumor effects.
🔬 复现建议：代谢物-蛋白互作的鉴定方法（如本文中衣康酸-G6PD的结合验证）可直接用于验证乳酸与PCAF的相互作用。推荐采用热稳定性分析(CETSA)、表面等离子共振(SPR)或DARTS等技术确认乳酸-PCAF的直接结合。
📊 Figure 5 | 4-辛基衣康酸将促癌巨噬细胞重编程为抗癌表型
Figure 5
Figure 5 | Fig. 5: 4-Octyl itaconate (Octyl Ita) reprograms pro-tumor macrophages into anti-tumor macrophages. Treatment with the cell-permeable itaconate derivative Octyl Ita converts immunosuppressive M2-like TAMs into anti-tumor M1-like macrophages. Multi-omics analysis (transcriptomics + proteomics + metabolomics) reveals itaconate rewires both cancer cell and macrophage metabolism through G6PD-PPP axis.
🔬 复现建议：用户可尝试类似策略：使用LDHA抑制剂（如FX11）或乳酸转运抑制剂阻断乳酸产生/摄取，观察巨噬细胞极化状态改变。乳酸对巨噬细胞极化的影响可作为用户课题的延伸方向。
📊 Figure 6 | 体内外治疗验证及工作模型
Figure 6
Figure 6 | Fig. 6: Therapeutic efficacy of 4-octyl itaconate in vivo and ex vivo. Octyl Ita treatment reduces tumor growth in subcutaneous and orthotopic lung cancer mouse models, as well as in ex vivo human precision-cut lung slices (PCLS). Combination therapy with immune checkpoint inhibitors shows enhanced anti-tumor efficacy. Working model: IRG1/itaconate → G6PD inhibition → PPP suppression → metabolic rewiring of TME → anti-tumor immunity.
🔬 复现建议：用户的课题可参考本文的体内验证策略：利用原位肺癌模型观察LDHA抑制剂处理后RhoA乳酸化状态和mitoxyperiosis水平的变化。ex vivo人源肺切片培养(PCLS)模型也值得在后续研究中引入。
🎯 Hermes + Claude 深度评述

Claude评估团队对本论文进行了5维度严格评分（总分43/50），一致认为这是今日推送中的最优选择：

✅ 核心优势：
1. 方法论标杆级：空间代谢组学 + 单细胞测序 + 多组学整合的复合研究设计
2. 完整因果链：从空间定位(Fig1)→细胞溯源(Fig2)→功能验证(Fig3)→机制解析(Fig4)→治疗验证(Fig6)
3. 可借鉴性极强：空间代谢组学工作流可迁移至用户的乳酸代谢/肿瘤代谢研究
4. 转化前景清晰：4-辛基衣康酸(Octyl Ita)已有成药性基础

⚠️ 不足：衣康酸免疫调节功能已有先例，概念创新性(8分)略逊于方法论创新

🔬 课题借鉴：本研究的空间代谢组学+scRNA-seq整合分析流程可直接用于用户的Warburg效应相关研究。通过空间代谢组学定位乳酸在肿瘤区域的分布异质性，结合scRNA-seq鉴定产乳酸的关键细胞亚群，可为"乳酸→PCAF→RhoA乳酸化"假说提供前所未有的空间证据。

📌 一句话总结

IRG1/衣康酸通过抑制G6PD重编程肺肿瘤微环境代谢，将促癌巨噬细胞转化为抗癌表型——空间代谢组学+单细胞测序+多组学整合的标杆式工作流，为肿瘤代谢免疫研究提供了可直接复用的方法论框架。

📄 Cell Metabolism  |  DOI: 10.1016/j.cmet.2026.05.005  |  PMID: 42235511

📅 发表日期: 2026-06-03  |  Generated by Hermes Paper Recommender